Full-Time

Digital Enterprise Capabilities Senior Manager

Clinical Systems Operations

Posted on 5/9/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$135.2k - $202.8k/yr

Pennsylvania, USA + 1 more

More locations: California, USA

Remote

Category
IT & Security (2)
,
Required Skills
Veeva
Agile
Requirements
  • Strong working knowledge of Clinical systems including Medidata (e.g., Rave), Veeva Clinical (eTMF, CTMS, CDMS, SSU), and eClinical Solutions, Elluminate or similar clinical data factory
  • Demonstrated expertise in GxP compliance, 21 CFR Part 11, computer systems validation, and Computer Software Assurance principles
  • Proven ability to manage the full lifecycle of clinical systems, including support operations (Level 2), change control, system performance monitoring, documentation, and infrastructure planning
  • Experience defining and managing product roadmaps, backlogs, KPIs, and SLAs aligned with Clinical business priorities
  • Strong vendor management skills, including contract oversight, performance monitoring, and service optimization
  • Excellent communication, collaboration, and stakeholder engagement skills; able to work across IT, Quality, and Clinical functions
  • Solid understanding of Agile methodologies and experience delivering SaaS-based or cloud-enabled solutions
  • Strong problem-solving, analytical, organizational, and follow-up skills with attention to detail
  • Experience working in a regulated, fast-paced, and cross-functional environment supporting clinical development processes
  • Bachelor's degree (B.A. or B.S.) from a four-year accredited college or university and 5-7 years of relevant experience; or equivalent combination of education and experience
  • Certified Veeva Clinical Operations Administrator a plus
Responsibilities
  • Partner with Clinical Development Operations business capability owners and DEC R&D Business Partners to ensure ongoing alignment, enhancement, and lifecycle management of capability-aligned digital systems supporting key clinical capabilities (e.g., trial planning, CTMS, EDC, site and investigator management)
  • Collaborate across Jazz Clinical business functions, DEC product teams, and external vendors to manage day-to-day system operations and ensure business continuity
  • Own the backlog, execution of change control and validation activities in compliance with Jazz’s GxP, SDLC, and change management standards; ensure seamless coordination with business stakeholders for impact assessments, testing, and rollout
  • Maintain and continuously improve operational system documentation, including validation packages, configuration records, SOPs, and test scripts for both GxP and non-GxP systems
  • Drive issue resolution and technology optimization in partnership with vendors, product managers, and clinical capability leads, ensuring technology solutions are harmonized with evolving business processes
  • Plan and lead core system ownership responsibilities, including user access reviews, system performance monitoring, upgrade planning, system health checks, disaster recovery testing, and license and vendor contract management
  • Support product roadmapping and release planning by providing input on system enhancement opportunities, business value drivers, and technical feasibility
  • Manage aspects of system operations and smaller-scale projects, including scope definition, resource planning, timelines, and budget tracking in collaboration with product and portfolio teams
  • Ensure alignment with Jazz Quality and Compliance functions to uphold the appropriate level of validation, risk mitigation, and operational control across the system lifecycle
  • Facilitate the operationalization of newly implemented systems by collaborating with DEC Business Partners/Capability Leads and ensuring a smooth transition from project delivery to steady-state support
Desired Qualifications
  • Certified Veeva Clinical Operations Administrator a plus

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex achieved $1.1B sales in 2025, growing 9% year-over-year.
  • Recorded $4.3B revenue in 2025, guiding $4.25B-$4.5B for 2026.
  • Renee Gala became CEO August 2025, driving 90% revenue growth.

What critics are saying

  • Epidiolex generics erode 25% of revenue within 12-24 months.
  • Japan Phase 3 Epidiolex failure blocks Asian market entry immediately.
  • Chimerix dordaviprone NDA rejected August 2025, wasting $935M.

What makes Jazz Pharmaceuticals unique

  • Focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Acquired GW Pharmaceuticals in 2021, adding blockbuster Epidiolex for epilepsy.
  • Vyxeos from 2016 Celator acquisition treats acute myeloid leukemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.